ALX ONCOLOGY HOLDINGS INC Investing Cash Flow
ALX ONCOLOGY HOLDINGS INC (ALXO) reported Investing Cash Flow of -$98.51 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-06
- ALX ONCOLOGY HOLDINGS INC net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $6.52M, a 70.77% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$105.04M, a 479.95% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $11.23M, a 66.15% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $21.39M, a 16.74% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC net cash provided by (used in) investing activities for fiscal 2025 was $82.59M, a 4.25% decline from fiscal 2024.
- ALX ONCOLOGY HOLDINGS INC net cash provided by (used in) investing activities for fiscal 2024 was $86.26M, a 93.15% increase from fiscal 2023.
- ALX ONCOLOGY HOLDINGS INC net cash provided by (used in) investing activities for fiscal 2023 was $44.66M.
- ALX ONCOLOGY HOLDINGS INC net cash provided by (used in) investing activities for fiscal 2022 was -$235.42M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$98.51M 10-Q · filed 2026-08-06 | -$87.28M derived: sum of 3 quarters · filed 2026-08-06 | -$65.89M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$105.04M 10-Q · filed 2026-05-08 | -$93.80M derived: sum of 2 quarters · filed 2026-05-08 | -$72.41M derived: sum of 3 quarters · filed 2026-05-08 | -$50.09M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $11.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $32.63M derived: sum of 2 quarters · filed 2026-03-09 | $54.94M derived: sum of 3 quarters · filed 2026-08-06 | $82.59M 10-K · filed 2026-03-09 |
| 2025-09-30 | $21.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $43.71M derived: sum of 2 quarters · filed 2026-08-06 | $71.35M 10-Q · filed 2025-11-07 | $104.54M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $22.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $49.96M 10-Q · filed 2026-08-06 | $83.14M derived: sum of 3 quarters · filed 2026-08-06 | $108.84M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $27.64M 10-Q · filed 2026-05-08 | $60.83M derived: sum of 2 quarters · filed 2026-05-08 | $86.52M derived: sum of 3 quarters · filed 2026-05-08 | $87.43M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $33.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $58.88M derived: sum of 2 quarters · filed 2026-03-09 | $59.78M derived: sum of 3 quarters · filed 2026-03-09 | $86.26M 10-K · filed 2026-03-09 |
| 2024-09-30 | $25.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $26.60M derived: sum of 2 quarters · filed 2025-11-07 | $53.07M 10-Q · filed 2025-11-07 | $36.41M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-06-30 | $907.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $27.38M 10-Q · filed 2025-08-12 | $10.71M derived: sum of 3 quarters · filed 2026-03-09 | $23.53M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-03-31 | $26.47M 10-Q · filed 2025-05-08 | $9.81M derived: sum of 2 quarters · filed 2026-03-09 | $22.62M derived: sum of 3 quarters · filed 2026-03-09 | $28.84M derived: sum of 4 quarters · filed 2026-03-09 |
| 2023-12-31 | -$16.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$3.85M derived: sum of 2 quarters · filed 2026-03-09 | $2.36M derived: sum of 3 quarters · filed 2026-03-09 | $44.66M 10-K · filed 2026-03-09 |
| 2023-09-30 | $12.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $19.03M derived: sum of 2 quarters · filed 2024-11-07 | $61.32M 10-Q · filed 2024-11-07 | $72.27M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | $6.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $48.51M 10-Q · filed 2024-08-12 | $59.45M derived: sum of 3 quarters · filed 2025-03-06 | $73.14M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | $42.30M 10-Q · filed 2024-05-09 | $53.24M derived: sum of 2 quarters · filed 2025-03-06 | $66.93M derived: sum of 3 quarters · filed 2025-03-06 | -$9.20M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $10.94M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $24.64M derived: sum of 2 quarters · filed 2025-03-06 | -$51.49M derived: sum of 3 quarters · filed 2025-03-06 | -$235.42M 10-K · filed 2025-03-06 |
| 2022-09-30 | $13.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$62.44M derived: sum of 2 quarters · filed 2023-11-13 | -$246.36M 10-Q · filed 2023-11-13 | -$250.88M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-06-30 | -$76.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$260.05M 10-Q · filed 2023-08-10 | -$264.57M derived: sum of 3 quarters · filed 2024-03-07 | -$264.97M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-03-31 | -$183.92M 10-Q · filed 2023-05-11 | -$188.44M derived: sum of 2 quarters · filed 2024-03-07 | -$188.84M derived: sum of 3 quarters · filed 2024-03-07 | -$188.84M derived: sum of 4 quarters · filed 2024-03-07 |
| 2021-12-31 | -$4.52M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | -$4.92M derived: sum of 2 quarters · filed 2024-03-07 | -$4.92M derived: sum of 3 quarters · filed 2024-03-07 | -$4.92M 10-K · filed 2024-03-07 |
| 2021-09-30 | -$398.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$398.00K derived: sum of 2 quarters · filed 2022-11-08 | -$405.00K 10-Q · filed 2022-11-08 | -$416.00K derived: sum of 4 quarters · filed 2023-03-09 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$7.00K 10-Q · filed 2022-08-08 | -$18.00K derived: sum of 3 quarters · filed 2023-03-09 | $613.00K derived: sum of 4 quarters · filed 2023-03-09 |
| 2021-03-31 | -$7.00K 10-Q · filed 2022-05-09 | -$18.00K derived: sum of 2 quarters · filed 2023-03-09 | $613.00K derived: sum of 3 quarters · filed 2023-03-09 | $613.00K derived: sum of 4 quarters · filed 2023-03-09 |
| 2020-12-31 | -$11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $620.00K derived: sum of 2 quarters · filed 2023-03-09 | $620.00K derived: sum of 3 quarters · filed 2023-03-09 | $610.00K 10-K · filed 2023-03-09 |
| 2020-09-30 | $631.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $631.00K derived: sum of 2 quarters · filed 2021-11-12 | $621.00K 10-Q · filed 2021-11-12 | $683.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$10.00K 10-Q · filed 2021-08-12 | $52.00K derived: sum of 3 quarters · filed 2022-02-28 | $52.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$10.00K 10-Q · filed 2021-05-17 | $52.00K derived: sum of 2 quarters · filed 2022-02-28 | $52.00K derived: sum of 3 quarters · filed 2022-02-28 | |
| 2019-12-31 | $62.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $62.00K derived: sum of 2 quarters · filed 2022-02-28 | -$353.00K 10-K · filed 2022-02-28 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$415.00K 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | -$415.00K 10-Q · filed 2020-08-27 | |||
| 2018-12-31 | -$653.00K 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |